354 results on '"Guillerm, Gaelle"'
Search Results
52. Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Poor Karnofsky Performance Status Score. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
- Author
-
Saraceni, Francesco, primary, Labopin, Myriam, additional, Forcade, Edouard, additional, Kroger, Nicolaus, additional, Socié, Gerard, additional, Niittyvuopio, Riitta, additional, Cornelissen, Jan, additional, Labussière-Wallet, Hélène, additional, Blaise, Didier, additional, Choi, Goda, additional, Byrne, J., additional, Guillerm, Gaelle, additional, Lamy, Thierry, additional, Esteve, Jordi, additional, Bazarbachi, Ali, additional, Savani, Bipin, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional
- Published
- 2020
- Full Text
- View/download PDF
53. High-dose melphalan followed by a second bone marrow transplantation in early relapse of acute myeloid leukemia after bone marrow transplantation in children
- Author
-
Tempescul, Adrian, Ianotto, Jean-Christophe, Eveillard, Jean-Richard, Guillerm, Gaelle, Berthou, Christian, Marion, Veronique, and De Braekeleer, Marc
- Published
- 2008
- Full Text
- View/download PDF
54. Gestion personnalisée du sang (GPS) : expérience du CHRU de Brest
- Author
-
Le Niger, Catherine, primary, Vadam, Christophe, additional, Grayo, Claire Marine, additional, Le Roy, Julie, additional, Huet, Olivier, additional, Bodenes, Laeticia, additional, Aubron, Cécile, additional, Huiban, Brigitte, additional, Nguyen, Vinh, additional, Oilleau, Jean Ferreol, additional, Couturier, Marie Anne, additional, Guillerm, Gaelle, additional, Le Guen, Patrick, additional, Galinat, Hubert, additional, Carré, Jean-Luc, additional, Coutté, Marie-Bénédicte, additional, and Ozier, Yves, additional
- Published
- 2019
- Full Text
- View/download PDF
55. Genetic diagnosis of primary immunodeficiencies: A survey of the French national registry
- Author
-
Mahlaoui, Nizar, primary, Picard, Capucine, additional, Bach, Perrine, additional, Costes, Laurence, additional, Courteille, Virginie, additional, Ranohavimparany, Anja, additional, Alcaïs, Alexandre, additional, Jais, Jean-Philippe, additional, Fischer, Alain, additional, Bellanné-Chantelot, Christine, additional, Bustamante, Jacinta, additional, Chollet-Martin, Sylvie, additional, Drouet, Christian, additional, Fremeaux-Bacchi, Véronique, additional, Kannengiesser, Caroline, additional, Girardin, Virginie, additional, Lambert, Nathalie, additional, Proulle, Valérie, additional, Rosain, Jérémie, additional, Stasia, Marie José, additional, Lyonnet, Dominique Stoppa, additional, Theodorou, Ioannis, additional, Abou-Chahla, Wadih, additional, Adoue, Daniel, additional, Aladjidi, Nathalie, additional, Amoura, Zahir, additional, Armari-Alla, Corinne, additional, Bader-Meunier, Brigitte, additional, Barlogis, Vincent, additional, Bayart, Sophie, additional, Bertrand, Yves, additional, Blanche, Stéphane, additional, Bodet, Damien, additional, Bonnotte, Bernard, additional, Borie, Raphaël, additional, Boutard, Patrick, additional, Briandet, Claire, additional, Brion, Jean-Paul, additional, Brouard, Jacques, additional, Carausu, Liana, additional, Catherinot, Emilie, additional, Cheikh, Nathalie, additional, Cohen-Beaussant, Sarah, additional, Couderc, Louis-Jean, additional, Cougoul, Pierre, additional, Couillault, Gérard, additional, de Saint Basile, Geneviève, additional, Devoldere, Catherine, additional, Deville, Anne, additional, Dore, Eric, additional, Dulieu, Fabienne, additional, Durieu, Isabelle, additional, Werle, Natacha Entz, additional, Fieschi, Claire, additional, Fouyssac, Fanny, additional, Frange, Pierre, additional, Gajdos, Vincent, additional, Galicier, Lionel, additional, Gandemer, Virginie, additional, Gardembas, Martine, additional, Gaud, Catherine, additional, Grosbois, Bernard, additional, Guffroy, Aurélien, additional, Guitton, Corinne, additional, Guillerm, Gaelle, additional, Hachulla, Eric, additional, Hamidou, Mohamed, additional, Haro, Sophie, additional, Hatchuel, Yves, additional, Hermine, Olivier, additional, Hoarau, Cyrille, additional, Hoen, Bruno, additional, Hot, Arnaud, additional, Humbert, Sébastien, additional, Jaccard, Arnaud, additional, Jacquot, Serge, additional, Jaussaud, Rolland, additional, Jeandel, Pierre-Yves, additional, Jeziorski, Eric, additional, Kebaili, Kamila, additional, Korganow, Anne-Sophie, additional, Lambotte, Olivier, additional, Lanternier, Fanny, additional, Larroche, Claire, additional, Le Quellec, Alain, additional, Le Moigne, Emmanuelle, additional, Le Moing, Vincent, additional, Launay, David, additional, Lebranchu, Yvon, additional, Lecuit, Marc, additional, Lefevre, Guillaume, additional, Lemal, Richard, additional, Li-Thiao-Te, Valérie, additional, Lortholary, Olivier, additional, Malphettes, Marion, additional, Marie-Cardine, Aude, additional, Silva, Nicolas Martin, additional, Masseau, Agathe, additional, Massot, Christian, additional, Mazingue, Françoise, additional, Merlin, Etienne, additional, Michel, Gérard, additional, Millot, Frédéric, additional, Monlibert, Béatrice, additional, Monpoux, Fabrice, additional, Moshous, Despina, additional, Mouthon, Luc, additional, Munzer, Martine, additional, Neven, Bénédicte, additional, Nove-Josserand, Raphaëlle, additional, Nouar, Dalila, additional, Oksenhendler, Eric, additional, Ouachée-Chardin, Marie, additional, Pagnier, Anne, additional, Pasquet, Marlène, additional, Pellier, Isabelle, additional, Perel, Yves, additional, Perlat, Antoinette, additional, Piguet, Christophe, additional, Plantaz, Dominique, additional, Quartier, Pierre, additional, Rieux-Laucat, Frédéric, additional, Roblot, Pascal, additional, Rohrlich, Pierre-Simon, additional, Royer, Bruno, additional, Salle, Valéry, additional, Sarrot-Reynauld, Françoise, additional, Servettaz, Amélie, additional, Stephan, Jean-Louis, additional, Schleinitz, Nicolas, additional, Suarez, Felipe, additional, Swiader, Laure, additional, Taque, Sophie, additional, Thomas, Caroline, additional, Tournilhac, Olivier, additional, Thumerelle, Caroline, additional, Vannier, Jean-Pierre, additional, and Viallard, Jean-François, additional
- Published
- 2019
- Full Text
- View/download PDF
56. Real Life Study on Allogeneic Hematopoietic Cell Transplantation Practice According to International Guidelines and Its Impact on Survival in Acute Myeloid Leukemia French Population
- Author
-
Abed, Loic, Mounier, Morgane, Robin, Marie, Nguyen Quoc, Stephanie, Raus, Nicole, Berceanu, Anna, Chantepie, Sylvain, Pigneux, Arnaud, Forcade, Edouard, Bay, Jacques-Olivier, Francois, Sylvie, Guillerm, Gaëlle, Mear, Jean-Baptiste, Caillot, Denis, Mohty, Mohamad, Dulery, Remy, Contentin, Nathalie, Jubert, Charlotte, Monnereau, Alain, Orazio, Sebastien, Troussard, Xavier, Cornet, Edouard, Sobh, Mohamad, Maynadie, Marc, and Michallet, Mauricette
- Published
- 2021
- Full Text
- View/download PDF
57. Chromosome 13 abnormalities identified by FISH analysis and serum β2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy
- Author
-
Facon, Thierry, Avet-Loiseau, Hervé, Guillerm, Gaëlle, Moreau, Philippe, Geneviève, Franck, Zandecki, Marc, Laı̈, Jean-Luc, Leleu, Xavier, Jouet, Jean-Pierre, Bauters, Francis, Harousseau, Jean-Luc, Bataille, Régis, and Mary, Jean-Yves
- Published
- 2001
- Full Text
- View/download PDF
58. Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the société Francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC)
- Author
-
Gilardin, Laurent, Delignat, Sandrine, Peyron, Ivan, Ing, Mathieu, Lone, Yu-Chun, Gangadharan, Bagirath, Michard, Baptiste, Kherabi, Yousra, Sharma, Meenu, Pashov, Anastas, Toutirais, Olivier, Loiseau, Pascale, Veyradier, Agnès, Kaveri, Srini, Maillere, Bernard, Coppo, Paul, Lacroix-Desmazes, Sébastien, Chatillon, Jean-François, Hamieh, Mohamad, Bayeux, Florence, Abasq, Claire, Fauquembergue, Emilie, Drouet, Aurélie, Guisier, Florian, Latouche, Jean-Baptiste, Musette, Philippe, Coignard-Biehler, Hélène, Mahlaoui, Nizar, Pilmis, Benoit, Barlogis, Vincent, Brosselin, Pauline, de Vergnes, Nathalie, Debré, Marianne, Malphettes, Marion, Frange, Pierre, Catherinot, Emilie, Pellier, Isabelle, Durieu, Isabelle, Perlat, Antoinette, Royer, Bruno, Le Quellec, Alain, Jeziorski, Eric, Fischer, Alain, Lortholary, Olivier, Aaron+, Laurent, Adoue, Daniel, Aguilar, Claire, Aladjidi, Nathalie, Alcaïs, Alexandre, Amoura, Zahir, Arlet, Philippe, Armari-Alla, Corinne, Bader-Meunier, Brigitte, Bayart, Sophie, Bienvenu, Boris, Blanche, Stéphane, Bodet, Damien, Bonnotte, Bernard, Borie, Raphael, Boutard, Patrick, Briandet, Claire, Brion, Jean-Paul, Brouard, Jacques, Cohen-Beaussant, Sarah, Costes, Laurence, Couderc, Louis-Jean, Cougoul, Pierre, Courteille, Virginie, de Saint Basile, Geneviève, Devoldere, Catherine, Deville, Anne, Donadieu, Jean, Doré, Eric, Dulieu, Fabienne, Edan, Christine, Entz-Werlé, Natacha, Fieschi, Claire, Forestier, Amandine, Fouyssac, Fanny, Gajdos, Vincent, Galicier, Lionel, Gandemer, Virginie, Gardembas, Martine, Gaud, Catherine, Guillerm, Gaelle, Hachulla, Eric, Hamidou, Mohamed, Hermine, Olivier, Hoarau, Cyrille, Humbert, Sebastien, Jaccard, Arnaud, Jacquot, Serge, Jais, Jean-Philippe, Jaussaud, Roland, Jeandel, Pierre-Yves, Kebaili, Kamila, Korganow, Anne-Sophie, Lambotte, Olivier, Lanternier, Fanny, Larroche, Claire, Lascaux, Anne-Sophie, Le Moigne, Emmanuelle, Le Moing, Vincent, Lebranchu, Yvon, Lecuit, Marc, Lefèvre, Guillaume, Lemal, Richard, Te, Valérie Li Thiao, Marie-Cardine, Aude, Silva, Nicolas Martin, Masseau, Agathe, Massot, Christian, Mazingue, Françoise, Merlin, Etienne, Monlibert, Béatrice, Monpoux, Fabrice, Moshous, Despina, Mouthon, Luc, Munzer, Martine, Neven, Bénédicte, Nove-Josserand, Raphaëlle, Oksenhendler, Eric, Ouachée-Chardin, Marie, Oudot, Caroline, Pagnier, Anne, Pasquali, Jean-Louis, Pasquet, Marlène, Perel, Yves, Picard, Capucine, Piguet, Christophe, Plantaz, Dominique, Provot, Johan, Quartier, Pierre, Rieux-Laucat, Frédéric, Roger, Pierre-Marie, Rohrlich, Pierre-Simon, Rubié, Hervé, Salle, Valéry, Sarrot-Reynauld, Françoise, Servettaz, Amélie, Stephan, Jean-Louis, Schleinitz, Nicolas, Suarez, Felipe, Swiader, Laure, Taque, Sophie, Thomas, Caroline, Tournilhac, Olivier, Thumerelle, Caroline, Tron, François, Viallard, Jean-François, Roux, Clément, Tifratene, K, Socie, G., Galambrun, C., Bertrand, Yves, Rialland, F., Jubert, C, Pochon, C, Paillard, C., Sirvent, A., Nelken, B., Vannier, Jean-Pierre, Freycon, C, Beguin, Y, Raus, N, Yakoub-Agha, I., Mohty, M., Dalle, J-H, Michel, Gérard, Pradier, C., Peffault de Latour, R., Rohrlich, P-S, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Centre de Recherche des Cordeliers (CRC), Université Pierre et Marie Curie - Paris 6 (UPMC)-École Pratique des Hautes Études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Greffes d'Epitheliums et Regulation de l'Activation Lymphocytaire, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Les Hôptaux universitaires de Strasbourg (HUS), CHU Strasbourg, Institut Stephan Angeloff, Réseau International des Instituts Pasteur (RIIP), Immunogénétique humaine, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hématologie Biologique [Béclère], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Antoine Béclère [Clamart], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Département d'Ingénierie et d'Etudes des Protéines, Commissariat à l'énergie atomique et aux énergies alternatives (CEA), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), UNIROUEN - UFR Santé (UNIROUEN UFR Santé), Normandie Université (NU)-Normandie Université (NU), Service de dermatologie (Dermato - BREST), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Génétique du cancer et des maladies neuropsychiatriques (GMFC), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Rouen, Physiopathologie, Autoimmunité, maladies Neuromusculaires et THErapies Régénératrices (PANTHER), Service de Dermatologie [Rouen], Hôpital Charles Nicolle [Rouen], Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hématologie pédiatrique, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'immuno-hématologie pédiatrique [CHU Necker], Service d'Immunopathologie [Hôpital Saint-Louis, Paris], Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Unité d'Immunologie Hématologie et Rhumatologie Pédiatrique [Necker, Paris], Hôpital Foch [Suresnes], Innate Immunity and Immunotherapy (CRCINA-ÉQUIPE 7), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université d'Angers (UA)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes), Service de Médecine Interne - Centre Hospitalier Lyon Sud, Hospices Civils de Lyon (HCL)-Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Service de Médecine interne et immunologie clinique [Rennes] = internal medicine and clinical immunology [Rennes], CHU Pontchaillou [Rennes], CHU Amiens-Picardie, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Collège de France - Chaire Médecine expérimentale (A. Fischer), Collège de France (CdF (institution)), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Département de Pédiatrie et maladies infectieuses [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Service d'Hémato-oncologie Pédiatrique, CHU Bordeaux [Bordeaux]-Hôpital Pellegrin, Génétique Humaine des Maladies Infectieuses (Inserm U980), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Immunologie et des Maladies Infectieuses (CIMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS), Service Médecine Interne et immunologie clinique [CHU Toulouse], Pôle Maladies de l'appareil digestif [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital de la Tronche, Département d'Immunologie, hématologie et rhumatologie pédiatriques [Hôpital Necker-Enfants malades - APHP], Hématogoie pédiatrique, hôpital Sud, Laboratoire de Mathématiques Nicolas Oresme (LMNO), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Centre National de la Recherche Scientifique (CNRS), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS BFC)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Physiopathologie et Epidémiologie des Maladies Respiratoires (PHERE (UMR_S_1152 / U1152)), Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Côte de Nacre [CHU Caen], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Service de Pédiatrie Enfants - Hématologie Oncologie [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service des Maladies Infectieuses, CHU Grenoble, Service de Pédiatrie Médicale [Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Nutrition et Neurobiologie intégrée (NutriNeuro), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA)-Université Sciences et Technologies - Bordeaux 1 (UB)-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique, Developpement Normal et Pathologique du Système Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'Hémato-oncologie Pédiatrique [CHU Nice], Centre Hospitalier Universitaire de Nice (CHU Nice), CHU Trousseau [APHP], Centre d'Investigation Clinique [CHU Clermont-Ferrand] (CIC 1405), Institut National de la Santé et de la Recherche Médicale (INSERM)-Direction de la recherche clinique et de l’innovation [CHU Clermont-Ferrand] (DRCI), CHU Clermont-Ferrand-CHU Clermont-Ferrand, Département d'Oncologie Pédiatrique [CHU Hautepierre, Strasbourg], Hôpital de Hautepierre [Strasbourg], Immunologie clinique [CHU St-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service d'Hématologie et d'Oncologie Pédiatrique [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine de l'enfant et de l'adolescent [CHU Rennes], Apoptosis and Tumor Progression (CRCINA-ÉQUIPE 9), Service Hématologie, Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de médecine interne [Nantes], Université de Nantes (UN)-Hôtel-Dieu-Centre hospitalier universitaire de Nantes (CHU Nantes), Université Paris Descartes - Faculté de Médecine (UPD5 Médecine), Université Paris Descartes - Paris 5 (UPD5), Cellules Dendritiques, Immunomodulation et Greffes, Université de Tours (UT), Ecole Polytechnique Fédérale de Lausanne (EPFL), Physiologie Moléculaire de la Réponse Immune et des Lymphoproliférations (PMRIL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Physiopathologie et biothérapies des maladies inflammatoires et autoimmunes, Service d'informatique médicale et biostatistiques [CHU Necker], Université de Reims Champagne-Ardenne (URCA), Institut d’Hémato-Oncologie Pédiatrique, Immunologie et chimie thérapeutiques (ICT), Cancéropôle du Grand Est-Centre National de la Recherche Scientifique (CNRS), service de Médecine Interne et d'Immunologie Clinique [AP-HP Hôpital Bicêtre], Université Paris-Sud - Paris 11 (UP11)-Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris (AP-HP), Internal Medicine, Paris, Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation, Catalysis, Synthesis of Biomolecules and Sustainable Development (CSB2D), Centre National de la Recherche Scientifique (CNRS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias (CHELTER), Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Unité de Biostatistique et de Recherche Clinique (UBRC), Dept of Physiology, McGill University = Université McGill [Montréal, Canada], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Institut Jean Godinot [Reims], UNICANCER, Service d'Immunopathologie Clinique, Service d'hématologie et immunologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Service de Pédiatrie médicale - Spécialités médicales [CHU Limoges], CHU Limoges, Service Immuno Hémato-Onco Pédiatrique, Sercice Hématologie, immunologie et oncologie pédiatrique [CHU Toulouse], Pôle Enfants [CHU Toulouse], Hôpital Pellegrin, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service Hématologie Infantile, Immunogenetics of pediatric autoimmune diseases (Equipe Inserm U1163), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), Clinique de médecine interne, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Département de Médecine Interne, Immunologie clinique et maladies infectieuses [CHU Reims], Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims), Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'Hématologie et d'Oncologie pédiatrique, Service d'hématologie clinique, Hôpital Hôtel-Dieu [Paris], Service de pneumologie pédiatrique, Hôpital Jeanne de Flandre [Lille]-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Protéines de défense des réponses immune et inflammatoire : identification, régulation et rôles physiopathologiques, Médecine Interne, CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Service de Pediatrie Debrousse, Hôpital Debrousse, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut de Combustion, Aérothermique, Réactivité et Environnement (ICARE), Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)-Institut des Sciences de l'Ingénierie et des Systèmes (INSIS - CNRS), Service d'Hématologie et d'Oncologie Médicale, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Service d'hémato-immuno-oncologie pédiatrique [Rouen], Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Etablissement français du sang [Poitiers] (EFS), Public Health Department, Hôpital de l'Archet, Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7), École pratique des hautes études (EPHE)-Université Paris Diderot - Paris 7 (UPD7)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Université Paris Diderot - Paris 7 (UPD7)-École pratique des hautes études (EPHE)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Antoine Béclère, Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP], Hôpital Charles Nicolle [Rouen]-CHU Rouen, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Université Paris Diderot - Paris 7 (UPD7)-CHU Saint Louis [APHP], CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Innate immunity and Immunotherapy (CRCINA - Département INCIT - Equipe 7), Centre de recherche de Cancérologie et d'Immunologie / Nantes - Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Service de médecine interne, Hôpital Universitaire d'Amiens, CHU Toulouse [Toulouse], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Centre d'Immunologie et de Maladies Infectieuses (CIMI), Service de médecine interne, hôpital Purpan, Hôpital Sud, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (HOTE GREFFON), Université de Franche-Comté (UFC)-Etablissement français du sang [Bourgogne-France-Comté] (EFS [Bourgogne-France-Comté])-Institut National de la Santé et de la Recherche Médicale (INSERM), Nutrition et Neurobiologie intégrée (NutriNeur0), Ecole nationale supérieure de chimie, biologie et physique-Institut Polytechnique de Bordeaux-Université Sciences et Technologies - Bordeaux 1-Institut National de la Recherche Agronomique (INRA)-Université Bordeaux Segalen - Bordeaux 2, Service d’oncologie hématologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], CIC - Clermont Ferrand, Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de médecine de l'enfant et de l'adolescent, CHU Pontchaillou [Rennes]-Hôpital Sud, Apoptose et Progression tumorale (CRCNA / Equipe 9), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche en Santé de l'Université de Nantes (IRS-UN), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest)-Hôpital Morvan [Brest], Lille Inflammation Research International Center (LIRIC), Université de Tours, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), CHU Toulouse [Toulouse]-Hôpital de Rangueil, Institute of Chemistry for Life and Health Sciences (i-CLEHS), Role of intra-Clonal Heterogeneity and Leukemic environment in ThErapy Resistance of chronic leukemias - Clermont Auvergne (CHELTER), Université Clermont Auvergne (UCA), McGill University, Institut Jean Godinot, CRLCC Jean Godinot, Université Paris Diderot - Paris 7 (UPD7)-Hôpital Robert Debré-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Hématologie pédiatrique, Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA), Unité d'Hémato-Oncologie, Hôpital des Enfants, CHU Saint-Etienne, Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rouen Normandie (UNIROUEN), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP], Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)-Institut des Sciences de l'Ingénierie et des Systèmes (INSIS), CHU Saint-Antoine [APHP], École pratique des hautes études (EPHE), Université Pierre et Marie Curie - Paris 6 (UPMC)-École pratique des hautes études (EPHE), Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes)-Centre National de la Recherche Scientifique (CNRS)-Université d'Angers (UA), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Chaire Médecine expérimentale (A. Fischer), Centre National de la Recherche Scientifique (CNRS)-Université de Caen Normandie (UNICAEN), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Recherche Agronomique (INRA)-Université Sciences et Technologies - Bordeaux 1-Institut Polytechnique de Bordeaux-Ecole nationale supérieure de chimie, biologie et physique, Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), CHU Pontchaillou [Rennes]-hôpital Sud, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Université Paris Diderot - Paris 7 (UPD7)-Hôpital Robert Debré-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)
- Subjects
Oncology ,medicine.medical_specialty ,Palliative care ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,Hematopoietic stem cell transplantation ,Donor lymphocyte infusion ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Treatment Failure ,Child ,ComputingMilieux_MISCELLANEOUS ,Retrospective Studies ,Transplantation ,Acute leukemia ,Chemotherapy ,Leukemia ,business.industry ,Palliative Care ,Hematopoietic Stem Cell Transplantation ,Hematology ,Precursor Cell Lymphoblastic Leukemia-Lymphoma ,medicine.disease ,Donor Lymphocytes ,Leukemia, Biphenotypic, Acute ,3. Good health ,Surgery ,Survival Rate ,Leukemia, Myeloid, Acute ,Treatment Outcome ,Lymphocyte Transfusion ,030220 oncology & carcinogenesis ,Acute Disease ,Disease Progression ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,business ,030215 immunology - Abstract
Allogeneic hematopoietic stem cell transplantation (SCT) contributes to improved outcome in childhood acute leukemia (AL). However, therapeutic options are poorly defined in the case of post-transplantation relapse. We aimed to compare treatment strategies in 334 consecutive children with acute leukemia relapse or progression after SCT in a recent 10-year period. Data could be analyzed in 288 patients (157 ALL, 123 AML and 8 biphenotypic AL) with a median age of 8.16 years at transplantation. The median delay from first SCT to relapse or progression was 182 days. The treatment consisted of chemotherapy alone (n=108), chemotherapy followed by second SCT (n=70), supportive/palliative care (n=67), combination of chemotherapy and donor lymphocyte infusion (DLI; n=30), or isolated reinfusion of donor lymphocytes (DLI; n=13). The median OS duration after relapse was 164 days and differed according to therapy: DLI after chemotherapy=385 days, second allograft=391 days, chemotherapy=174 days, DLI alone=140 days, palliative care=43 days. A second SCT or a combination of chemotherapy and DLI yielded similar outcome (hazard ratio (HR)=0.85, P=0.53) unlike chemotherapy alone (HR=1.43 P=0.04), palliative care (HR=4.24, P
- Published
- 2017
- Full Text
- View/download PDF
59. Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT).
- Author
-
Saraceni, Francesco, Labopin, Myriam, Forcade, Edouard, Kröger, Nicolaus, Socié, Gerard, Niittyvuopio, Riitta, Cornelissen, Jan J., Labussière‐Wallet, Hélène, Blaise, Didier, Choi, Goda, Byrne, Jenny L., Guillerm, Gaelle, Marchand, Tony, Esteve, Jordi, Bazarbachi, Ali, Savani, Bipin, Olivieri, Attilio, Nagler, Arnon, and Mohty, Mohamad
- Subjects
KARNOFSKY Performance Status ,ACUTE myeloid leukemia ,STEM cell transplantation ,ACUTE leukemia ,BONE marrow - Abstract
Limited data are currently available on the outcome of patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (allo‐SCT) with a reduced performance status. We herein present the results of a registry study on 2,936 AML patients undergoing allo‐SCT in first remission (CR1) with a Karnofsky Performance Status (KPS) score less than or equal to 80%. Two‐year leukemia‐free survival (LFS), overall survival (OS) and graft‐versus‐host disease (GVHD)‐free, and relapse‐free survival (GRFS) rates were 54%, 59%, and 41%, respectively. In multivariable analysis, patients with a KPS score = 80% had lower non‐relapse mortality (NRM) and superior OS in comparison to patients with a KPS score <80% (p < 0.001). In the subgroup of patients with a KPS score =80%, a reduced‐intensity conditioning (RIC) regimen was associated with an increased risk of relapse (p = 0.002) and lower GRFS (p < 0.001) compared to myeloablative conditioning (MAC). Differently, in patients with a KPS score <80%, a RIC regimen resulted in lower NRM (p < 0.001), whereas relapse incidence did not differ, thus leading to an improved GRFS (p = 0.008) as compared to MAC. A transplant from a matched sibling donor (MSD) was associated with a reduced incidence of grade III‐IV acute GVHD (p < 0.01) and NRM (p < 0.01) in comparison to other donor types. In conclusion, allo‐SCT appears feasible in AML patients with a jeopardized KPS score. Survival is significantly affected by the conditioning intensity, which should be adjusted according to the severity of KPS impairment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
60. Allogeneic Hematopoietic Stem Cell Transplantation Improves Outcome of Elderly Patients with Acute Myeloid Leukemia in First Complete Remission: A Time-Dependent and Multistate Analysis from the French Innovative Leukemia Organization
- Author
-
Devillier, Raynier, primary, Forcade, Edouard, additional, Garnier, Alice, additional, Thepot, Sylvain, additional, Guillerm, Gaelle, additional, Hicheri, Yosr, additional, Bulabois, Claude-Eric, additional, Lioure, Bruno, additional, Roth Guepin, Gabrielle, additional, Dumas, Pierre-Yves, additional, Peterlin, Pierre, additional, Hunault, Mathilde, additional, Chevallier, Patrice, additional, Rubio, Marie Thérèse, additional, Blaise, Didier, additional, Cahn, Jean-Yves, additional, Ifrah, Norbert, additional, Vey, Norbert, additional, Pigneux, Arnaud, additional, Recher, Christian, additional, and Huynh, Anne, additional
- Published
- 2018
- Full Text
- View/download PDF
61. CPX-351, un nouveau 3+7 pour les leucémies aiguës myéloïdes secondaires du sujet âgé ?
- Author
-
Civi, Lanig, additional, Ianotto, Jean-Christophe, additional, and Guillerm, Gaelle, additional
- Published
- 2018
- Full Text
- View/download PDF
62. Outcome of Ph negative myeloproliferative neoplasms transforming to accelerated or leukemic phase
- Author
-
Mollard, Lise-Marie, primary, Chauveau, Aurélie, additional, Boyer-Perrard, Françoise, additional, Douet-Guilbert, Nathalie, additional, Houot, Roch, additional, Quintin-Roué, Isabelle, additional, Couturier, Marie-Anne, additional, Dagorne, Anaig, additional, Malou, Mohamed, additional, Le Calloch, Ronan, additional, Luycx, Odile, additional, Thepot, Sylvain, additional, Hunault, Mathilde, additional, Guillerm, Gaelle, additional, Berthou, Christian, additional, Ugo, Valérie, additional, Lippert, Éric, additional, and Ianotto, Jean-Christophe, additional
- Published
- 2018
- Full Text
- View/download PDF
63. Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS
- Author
-
Chevallier, Patrice, Labopin, Marie, de La Tour, Régis Peffault, Lioure, Bruno, Bulabois, Claude-Eric, Huynh, Anne, Blaise, Didier, Turlure, Pascal, Daguindau, Etienne, Maillard, Natacha, Yakoub-Agha, Ibrahim, Guillerm, Gaelle, Delage, Jeremy, Contentin, Nathalie, Bay, Jacques-Olivier, Beckerich, Florence, Bourhis, Jean-Henri, Detrait, Marie, Vigouroux, Stéphane, Francois, Sylvie, Legrand, Faézeh, Guillaume, Thierry, Mohty, Mohamad, Tc, Sfgm, Centre hospitalier universitaire de Nantes (CHU Nantes), Pathologies biliaires, fibrose et cancer du foie, Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Pierre et Marie Curie - Paris 6 - UFR de Médecine Pierre et Marie Curie (UPMC), Université Pierre et Marie Curie - Paris 6 (UPMC), Service d'Hémato-oncologie [CHU Saint-Louis], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département d'Oncologie et Hématologie [Strasbourg], Les Hôpitaux Universitaires de Strasbourg (HUS), Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon, Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Lille Inflammation Research International Center - U 995 (LIRIC), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), CHRU Brest - Service d'Hématologie (CHU-Brest-Hemato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Laboratoire d'hématologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), CHU Clermont-Ferrand, Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Département d'hématologie [Gustave Roussy], Institut Gustave Roussy (IGR), Hospices Civils de Lyon (HCL), CHU Bordeaux [Bordeaux], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM), Centre Hospitalier Universitaire de Nice (CHU Nice), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Institut Pasteur de Lille, and Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)
- Subjects
Male ,Oncology ,Cancer Research ,Transplantation Conditioning ,reduced-toxicity conditioning regimen ,0302 clinical medicine ,allogeneic stem cell transplantation ,hemic and lymphatic diseases ,Antineoplastic Combined Chemotherapy Protocols ,Clofarabine ,Original Research ,reduced‐toxicity conditioning regimen ,Adenine Nucleotides ,Incidence (epidemiology) ,Hematopoietic Stem Cell Transplantation ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,3. Good health ,Fludarabine ,Leukemia, Myeloid, Acute ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,Vidarabine ,medicine.drug ,Adult ,medicine.medical_specialty ,Allogeneic transplantation ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Lower risk ,lcsh:RC254-282 ,Young Adult ,03 medical and health sciences ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Radiology, Nuclear Medicine and imaging ,Aged ,Retrospective Studies ,Acute myeloid leukemia ,business.industry ,fludarabine ,Clinical Cancer Research ,Surgery ,myelodysplastic syndrome ,Transplantation ,Regimen ,clofarabine ,Myelodysplastic Syndromes ,Arabinonucleosides ,business ,Busulfan ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology ,Follow-Up Studies ,030215 immunology - Abstract
International audience; We have retrospectively compared survivals between acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) patients who received either a clofarabine/busulfan (CloB2A2) or a fludarabine/busulfan (FB2A2) RIC regimen for allogeneic stem cell transplantation. Between 2009 and 2014, 355 allotransplanted cases were identified from the SFGM-TC registry as having received either the FB2A2 (n = 316, 56% males, median age: 59.2 years, AML 78.5%, first complete remission [CR1] 72%, median follow-up: 20 months) or the CloB2A2 (n = 39, 62% males, median age: 60.8 years, AML 62%, CR1 69%, median follow-up: 22.4 months) RIC regimen. In multivariate analysis, FB2A2 was associated with significant lower overall survival (OS, HR: 2.14; 95%CI: 1.05-4.35, P = 0.04) and higher relapse incidence (RI, HR: 2.17; 95%CI: 1.02-4.61, P = 0.04) and a trend for lower leukemia-free survival (LFS, HR: 1.75; 95%CI: 0.94-3.26, P = 0.08). These results were confirmed using a propensity score-matching strategy. However, when considering AML and MDS patients separately, the benefit of the CLOB2A2 regimen was restricted to AML patients (2-year OS FB2A2: 38% [14.5-61.6] vs. CloB2A2: 79.2% [62.9-95.4], P = 0.01; 2-year LFS FB2A2: 38% [16-59.9] vs. CloB2A2: 70.8% [52.6-89], P = 0.03). The better survivals were due to the lower risk of relapse in this CloB2A2 AML subgroup (2-year RI FB2A2: 41.2% [19-62.4] vs. CloB2A2: 16.7% [5-34.2], P = 0.05). This retrospective comparison suggests that the CloB2A2 RIC regimen can likely provide longer survival than that awarded by a FB2A2 RIC regimen and may become a new standard of care RIC regimen for allotransplanted AML patients. A prospective phase 3 randomized study is warranted.
- Published
- 2016
- Full Text
- View/download PDF
64. Randomized Phase 2 Trial of Lirilumab (anti-KIR monoclonal antibody, mAb) As Maintenance Treatment in Elderly Patients (pts) with Acute Myeloid Leukemia (AML): Results of the Effikir Trial
- Author
-
Vey, Norbert, primary, Dumas, Pierre-Yves, additional, Recher, Christian, additional, Gastaud, Lauris, additional, Lioure, Bruno, additional, Bulabois, Claude-Eric, additional, Pautas, Cecile, additional, Marolleau, Jean-Pierre, additional, Leprêtre, Stéphane, additional, Raffoux, Emmanuel, additional, Thomas, Xavier, additional, Hicheri, Yosr, additional, Bonmati, Caroline, additional, Quesnel, Bruno, additional, Rousselot, Philippe, additional, Castaigne, Sylvie, additional, Jourdan, Eric, additional, Malfuson, Jean Valère, additional, Guillerm, Gaelle, additional, Bouhris, Jean Henri, additional, Ojeda, Mario, additional, Hunault, Mathilde, additional, Ifrah, Norbert, additional, Gardin, Claude, additional, Delannoy, Andre, additional, Beautier, Lucile, additional, Paturel, Carine, additional, Andre, Pascale, additional, Zerbib, Robert, additional, Preudhomme, Claude, additional, Toubert, Antoine, additional, Dulphy, Nicolas, additional, Olive, Daniel, additional, Pigneux, Arnaud, additional, and Dombret, Herve, additional
- Published
- 2017
- Full Text
- View/download PDF
65. Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia
- Author
-
Lengline, Etienne, primary, Drenou, Bernard, additional, Peterlin, Pierre, additional, Tournilhac, Olivier, additional, Abraham, Julie, additional, Berceanu, Ana, additional, Dupriez, Brigitte, additional, Guillerm, Gaelle, additional, Raffoux, Emmanuel, additional, de Fontbrune, Flore Sicre, additional, Ades, Lionel, additional, Balsat, Marie, additional, Chaoui, Driss, additional, Coppo, Paul, additional, Corm, Selim, additional, Leblanc, Thierry, additional, Maillard, Natacha, additional, Terriou, Louis, additional, Socié, Gerard, additional, and de Latour, Regis Peffault, additional
- Published
- 2017
- Full Text
- View/download PDF
66. The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes
- Author
-
Le Clech, Lenaïg, primary, Sakka, Mehdi, additional, Meskar, Ahmed, additional, Kerspern, Helene, additional, Eveillard, Jean-Richard, additional, Berthou, Christian, additional, Buors, Caroline, additional, Lippert, Eric, additional, Guillerm, Gaelle, additional, Quintin-Roué, Isabelle, additional, Carré, Jean-Luc, additional, and Ianotto, Jean-Christophe, additional
- Published
- 2017
- Full Text
- View/download PDF
67. Impact of body-surface area on patients’ outcome in younger adults with acute myeloid leukemia
- Author
-
Cahu, Xavier, primary, Carré, Martin, additional, Recher, Christian, additional, Pigneux, Arnaud, additional, Hunault-Berger, Mathilde, additional, Vey, Norbert, additional, Chevallier, Patrice, additional, Delaunay, Jacques, additional, Gyan, Emmanuel, additional, Lioure, Bruno, additional, Bonmati, Caroline, additional, Himberlin, Chantal, additional, Hicheri, Yosr, additional, Guillerm, Gaelle, additional, Didier, Bouscary, additional, Larosa, Fabrice, additional, Ojeda-Uribe, Mario, additional, Bernard, Marc, additional, Bene, Marie C., additional, Ifrah, Norbert, additional, and Cahn, Jean-Yves, additional
- Published
- 2017
- Full Text
- View/download PDF
68. Post-transplantation long-term outcomes in 43 HIV-positive patients affected by high-risk or relapsed lymphoma.
- Author
-
Zanet, Ernesto, primary, Balsalobre, Pascual, additional, Taborelli, Martina, additional, Diez-Martin, Jose, additional, Re, Alessandro, additional, Ribera, Josep M., additional, Rupolo, Maurizio, additional, Genet, Philippe, additional, Serraino, Diego, additional, Guillerm, Gaelle, additional, Mazzucato, Mario, additional, Durante, Cristina, additional, Gabriel, Ian, additional, Cwynarski, Kate, additional, Conde Garcia, Eulogio, additional, Varela Gomez, Maria Rosario, additional, Ciancia, Rosanna, additional, Tirelli, Umberto, additional, and Michieli, Mariagrazia, additional
- Published
- 2017
- Full Text
- View/download PDF
69. Comparison of Mycophenolate Mofetil and a Calcineurin Inhibitor Versus Calcineurin Inhibitor Based Graft-Versus-Host-Disease Prophylaxis for Matched Unrelated Donor Transplant for Acute Myeloid Leukemia. a Study from the ALWP of the EBMT
- Author
-
Paviglianiti, Annalisa, Labopin, Myriam, Blaise, Didier, Socie, Gerard, Bulabois, Claude-Eric, Simand, Celestine, Fegueux, Nathalie, Gerbitz, Armin, Guillerm, Gaëlle, Maertens, Johan, Chevallier, Patrice, Huynh, Anne, Turlure, Pascal, Deconinck, Eric, Forcade, Edouard, Nagler, Arnon, and Mohty, Mohamad
- Published
- 2019
- Full Text
- View/download PDF
70. Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update
- Author
-
Rea, Delphine, Nicolini, Franck E, Tulliez, Michel, Rousselot, Philippe, Gardembas, Martine, Etienne, Gabriel, Guilhot, Francois, Guilhot, Joelle, Guerci, Agnès, Escoffre-Barbe, Martine, Legros, Laurence, Villemagne, Bruno, Guillerm, Gaëlle, Noel, Marie-Pierre, Coiteux, Valerie, Pignon, Jean-Michel, and Mahon, Francois-Xavier
- Published
- 2019
- Full Text
- View/download PDF
71. Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
- Author
-
Saraceni, Francesco, Labopin, Myriam, Forcade, Edouard, Kröger, Nicolaus, Socie, Gerard, Niittyvuopio, Riitta, Cornelissen, Jan J, Labussière-Wallet, Hélène, Blaise, Didier, Choi, Goda, Byrne, Jenny, Guillerm, Gaëlle, Lamy, Thierry, Esteve, Jordi, Bazarbachi, Ali, Savani, Bipin N., Nagler, Arnon, and Mohty, Mohamad
- Published
- 2019
- Full Text
- View/download PDF
72. Alloimmunisation post-allogreffe de cellules souches hématopoïétiques et syndrome du lymphocyte passager
- Author
-
Guerineau, Anne-Lise, Rebière, Vincent, Delépine, Pascal, Thibert, Jean-Baptiste, Guillerm, Gaëlle, and Leostic, Claudie
- Published
- 2019
- Full Text
- View/download PDF
73. High CD3+and CD34+peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
- Author
-
Czerw, Tomasz, Labopin, Myriam, Schmid, Christoph, Cornelissen, Jan J., Chevallier, Patrice, Blaise, Didier, Kuball, Juergen, Vigouroux, Stephane, Garban, Frederic, Lioure, Bruno, Fegueux, Nathalie, Clement, Laurence, Sandstedt, Anna, Maertens, Johan, Guillerm, Gaelle, Bordessoule, Dominique, Mohty, Mohamad, Nagler, Arnon, Czerw, Tomasz, Labopin, Myriam, Schmid, Christoph, Cornelissen, Jan J., Chevallier, Patrice, Blaise, Didier, Kuball, Juergen, Vigouroux, Stephane, Garban, Frederic, Lioure, Bruno, Fegueux, Nathalie, Clement, Laurence, Sandstedt, Anna, Maertens, Johan, Guillerm, Gaelle, Bordessoule, Dominique, Mohty, Mohamad, and Nagler, Arnon
- Abstract
Inconsistent results have been reported regarding the influence of graft composition on the incidence of graft versus host disease (GVHD), disease control and survival after reduced-intensity conditioning (RIC) allogeneic peripheral blood stem cell transplantation (allo-PBSCT). These discrepancies may be at least in part explained by the differences in disease categories, disease status at transplant, donor type and conditioning. The current retrospective EBMT registry study aimed to analyze the impact of CD3+ and CD34+ cells dose on the outcome of RIC allo-PBSCT in patients with acute myelogenous leukemia (AML) in first complete remission, allografted from HLA-matched unrelated donors (10 of 10 match). We included 203 adults. In univariate analysis, patients transplanted with the highest CD3+ and CD34+ doses (above the third quartile cut-off point values, amp;gt;347 x 10amp;lt;^amp;gt;6/kg and amp;gt;8.25 x 10amp;lt;^amp;gt;6/kg, respectively) had an increased incidence of grade III-IV acute (a) GVHD (20% vs. 6%, P = .003 and 18% vs. 7%, P = .02, respectively). There was no association between cellular composition of grafts and transplant-related mortality, AML relapse, incidence of chronic GVHD and survival. Neither engraftment itself nor the kinetics of engraftment were affected by the cell dose. In multivariate analysis, CD3+ and CD34+ doses were the only adverse predicting factors for grade III-IV aGVHD (HR = 3.6; 95% CI: 1.45-9.96, P = .006 and 2.65 (1.07-6.57), P = .04, respectively). These results suggest that careful assessing the CD3+ and CD34+ graft content and tailoring the cell dose infused may help in reducing severe acute GVHD risk without negative impact on the other transplantation outcomes.
- Published
- 2016
- Full Text
- View/download PDF
74. Nationwide Survey on the Use of Eltrombopag in Patients with Severe Aplastic Anemia: Report on Behalf of the French Reference Center for Aplastic Anemia
- Author
-
Lengline, Etienne, primary, Drenou, Bernard, additional, Peterlin, Pierre, additional, Tournilhac, Olivier, additional, Abraham, Julie, additional, Berceanu, Ana, additional, Dupriez, Brigitte, additional, Guillerm, Gaelle, additional, Raffoux, Emmanuel, additional, Sicre de Fontbrune, Flore, additional, Ades, Lionel, additional, Balsat, Marie, additional, Chaoui, Driss, additional, Coppo, Paul, additional, Corm, Selim, additional, Leblanc, Thierry, additional, Maillard, Natacha, additional, Terriou, Louis, additional, Socie, Gerard, additional, and Peffault de Latour, Regis, additional
- Published
- 2016
- Full Text
- View/download PDF
75. Allogeneic Stem Cell Transplantation in First Chronic Phase CML during the Last Decade: Retrospective Analysis of the National SFGM-TC Registry
- Author
-
Nicolini, Franck-Emmanuel, primary, Coiteux, Valerie, additional, Socie, Gerard, additional, Blaise, Didier, additional, Deconinck, Eric, additional, Chevallier, Patrice, additional, Rohrlich, Pierre Simon, additional, Nguyen, Stephanie, additional, Lamy, Thierry, additional, Bourhis, Jean-Henri, additional, Rubio, Marie-Thérèse, additional, Suarez, Felipe, additional, Cornillon, Jerome, additional, Damaj, Gandhi, additional, Maillard, Natacha, additional, Milpied, Noel, additional, Ceballos, Patrice, additional, Mohty, Mohamad, additional, Bulabois, Claude-Eric, additional, Lioure, Bruno, additional, Michel, Gerard, additional, Ifrah, Norbert, additional, Beguin, Yves, additional, Huynh, Anne, additional, Contentin, Nathalie, additional, Bay, Jacques-Olivier, additional, Bertrand, Yves, additional, Perel, Yves, additional, Dalle, Jean-Hugues, additional, Guillerm, Gaelle, additional, Malfuson, jean-Valere, additional, Marie-Cardine, Aude, additional, Michallet, Mauricette, additional, Raus, Nicole, additional, Balsat, Marie, additional, Labussiere, Helene, additional, Peffault De Latour, Regis, additional, and Yakoub-Agha, Ibrahim, additional
- Published
- 2016
- Full Text
- View/download PDF
76. Disease status and stem cell source impact on the results of reduced intensity conditioning transplant for Hodgkin lymphoma: a retrospective study from the French Society of Bone Marrow Graft Transplantation and Cellular Therapy
- Author
-
Marcais, Ambroise, Porcher, Raphael, Robin, Marie, Mohty, Mohamad, Michalet, Mauricette, Blaise, Didier, Tabrizi, Reza, Clement, Laurence, Ceballos, Patrice, Daguindau, Etienne, Bilger, Karin, Dhedin, Nathalie, Lapusan, Simona, Bay, Jacques Olivier, Pautas, C Eacutecile, Garban, Frederic, Ifrah, Norbert, Guillerm, Gaelle, Contentin, Nathalie, Bourhis, Jean-Henri, Yakoub Agha, Ibrahim, Bernard, Marc, Cornillon, Jerome, Milpied, Noel, Biostatistique et épidemiologie clinique, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hématologie greffe [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], Service d'hématologie et oncologie médicale, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie-Université de Montpellier (UM), Service d'hématologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon-CHU Grenoble-Hôpital Michallon, Service d'hématologie clinique [Avicenne], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris 13 (UP13)-Hôpital Avicenne [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service Hématologie, Hôpital Morvan [Brest]-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Laboratoire Hubert Curien [Saint Etienne] (LHC), Institut d'Optique Graduate School (IOGS)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Institut de Cancérologie de la Loire Lucien Neuwirth, Centre Hospitalier Universitaire de Saint-Etienne (CHU de Saint-Etienne), Haematology, and CHU Bordeaux [Bordeaux]
- Subjects
[SDV.CAN]Life Sciences [q-bio]/Cancer - Abstract
International audience; The role of reduced intensity allogeneic stem cell transplantation for the treatment of relapsed/refractory Hodgkin lymphoma remains controversial. We retrospectively analyzed 191 patients who underwent reduced intensity allogeneic stem cell transplantation between 1998 and 2008 for relapsed or refractory Hodgkin lymphoma and whose data were reported to the French registry. Median follow-up was 36 months. Estimated 3 years overall survival, progression free survival, cumulative incidence of relapse and cumulative incidence of non relapse mortality were 63%, 39%, 46%, and 16% respectively. There was no difference in outcome between patients in complete response and in partial response at time of transplantation for overall survival (70% versus 74%, no significant difference) and progression free survival (51% versus 42%, no significant difference). Patients with chemoresistant disease had a shorter overall survival (39% at 3 years p=0.0003) and progression free survival (18% at 3 years p=0.001) than patients in complete remission. The use of umbilical cord blood as stem cell source was associated with a poor outcome with an increased risk of death with a hazard ratio of 3.49 (95% confidence interval 1.26 to 9.63, p=0.016). The use of peripheral blood was associated with a better outcome for patients who where alive after 1 year post transplantation with a hazard ration of 0.38 (95% confidence interval 0.17 to 0.83, p=0.016). Disease status at transplantation remains the most important risk factor for outcome. Our data suggest that the use of peripheral blood should be preferred whereas umbilical cord blood should be used with caution.
- Published
- 2013
- Full Text
- View/download PDF
77. CloB2A2 Reduced-Intensity Conditioning (RIC) Regimen Prior to Allogeneic Stem Cell Transplantation Provides Significant Better Survival Compared to FB2A2 RIC Regimen in Adults with Acute Myeloid Leukemia (AML): A Study on Behalf of the SFGM-TC
- Author
-
Chevallier, Patrice, primary, Labopin, Myriam, additional, Peffault de la Tour, Regis, additional, Lioure, Bruno, additional, Cahn, Jean-Yves, additional, Huynh, Anne, additional, Blaise, Didier, additional, Turlure, Pascal, additional, Deconinck, Eric, additional, Maillard, Natacha, additional, Yakoub-Agha, Ibrahim, additional, Guillerm, Gaelle, additional, Fegueux, Nathalie, additional, Contentin, Nathalie, additional, Bay, Jacques-Olivier, additional, Beckerich, Florence, additional, Bourhis, Jean-Henri, additional, Detrait, Marie Y., additional, Vigouroux, Stephane, additional, François, Sylvie, additional, Legrand, Faezeh, additional, Raus, Nicole, additional, Guillaume, Thierry, additional, and Mohty, Mohamad, additional
- Published
- 2015
- Full Text
- View/download PDF
78. Allogeneic Hematopoietic Stem Cell Transplantation Offers Similar Outcome after Myeloablative and Sequential Conditioning Regimen in Patients with Primary Refractory or Relapsed Acute Myeloid Leukemia: A Study from the Societe Francaise De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)
- Author
-
Decroocq, Justine, primary, Itzykson, Raphael, additional, Vigouroux, Stéphane, additional, Michallet, Mauricette, additional, Yakoub-Agha, Ibrahim, additional, Beckerich, Florence, additional, Huynh, Anne, additional, Suarez, Felipe, additional, Chevallier, Patrice, additional, Nguyen quoc, Stephanie, additional, Lioure, Bruno, additional, Clément, Laurence, additional, Fegueux, Nathalie, additional, Contentin, Nathalie, additional, Guillerm, Gaelle, additional, Cornillon, Jérôme, additional, Carré, Martin, additional, Maillard, Natacha, additional, Mercier, Mélanie, additional, Mohty, Mohamad, additional, Beguin, Yves, additional, Bourhis, Jean-Henri, additional, Charbonnier, Amandine, additional, Jubert, Charlotte, additional, Dauriac, Charles, additional, Bay, Jacques-Olivier, additional, Blaise, Didier, additional, Deconinck, Eric, additional, Raus, Nicole, additional, Peffault de la Tour, Regis, additional, and Dhedin, Nathalie, additional
- Published
- 2015
- Full Text
- View/download PDF
79. RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Intermediate Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO & SFGM-TC French intergroup)
- Author
-
Tournilhac, Olivier, primary, Le Garff-Tavernier, Magali, additional, Tabrizi, Reza, additional, Nguyen quoc, Stephanie, additional, Legrand-Izadifar, Faize, additional, Chevallier, Patrice, additional, Reman, Oumedaly, additional, Tomowiak, Cecile, additional, Borel, Cecile, additional, Francois, Sylvie, additional, Turlure, Pascal, additional, Maury, Sébastien, additional, Guillerm, Gaelle, additional, Fornecker, Luc, additional, Lemal, Richard, additional, Quiney, Claire, additional, Bellanger, Carole, additional, Calvet, Laure, additional, Veronese, Lauren, additional, Cabrespine, Aurelie, additional, Coudert, Mathieu, additional, Bay, Jacques-Olivier, additional, Merle-Beral, Helene, additional, and Dhedin, Nathalie, additional
- Published
- 2015
- Full Text
- View/download PDF
80. Cutaneous granulocytic sarcoma and Koebner phenomenon in a context of myelodysplastic syndrome
- Author
-
Nizery-Guermeur, Constance, primary, Le Gall-Ianotto, Christelle, additional, Brenaut, Emilie, additional, Couturier, Marie-Anne, additional, Talagas, Matthieu, additional, Andrieu-Key, Sophie, additional, Guillerm, Gaelle, additional, Misery, Laurent, additional, and Karam, Allan, additional
- Published
- 2015
- Full Text
- View/download PDF
81. RIC Allogeneic Stem Cell Transplantation for High Risk CLL Followed By Preemptive MRD-Based Immunointervention - Final Results from the Phase II ICLL03 Ricac-Pmm Trial (FILO - SFGM-TC French intergroup)
- Author
-
Tournilhac, Olivier, Le Garff-Tavernier, Magali, Tabrizi, Reza, Nguyen-Quoc, Stephanie, Legrand-Izadifar, Faezeh, Combes, Patricia, Chevallier, Patrice, Reman, Oumedaly, Tomowiak, Cecile, Borel, Cecile, François, Sylvie, Turlure, Pascal, Maury, Sebastien, Guillerm, Gaelle, Vincent, Laure, Bilger, Karin, Lemal, Richard, Guieze, Romain, Quiney, Claire, Cabrespine, Aurelie, Bay, Jacques-Olivier, Leblond, Veronique, and Dhedin, Nathalie
- Published
- 2017
- Full Text
- View/download PDF
82. Comparison of Mobilized Peripheral Blood Stem Cells Versus Unmanipulated Bone Marrow Haploidentical Transplantation Using Post-Transplant Cyclophosphamide: A Retrospective Study of SFGM-TC in 176 Patients
- Author
-
Jacque, Nathalie, Lambert, Jérôme, Yakoub-Agha, Ibrahim, Tabrizi, Reza, Michallet, Mauricette, Deconinck, Eric, Thepot, Sylvain, Meunier, Mathieu, Peffault De Latour, Regis, Suarez, Felipe, Charbonnier, Amandine, Turlure, Pascal, Ceballos, Patrice, Guillerm, Gaelle, Michel, Gerard, Contentin, Nathalie, Marchand, Tony, Mannone, Lionel, Dalle, Jean-Hugues, Malfuson, Jean Valère, Lioure, Bruno, Rubio, Marie Thérèse, and Nguyen, Stephanie
- Published
- 2017
- Full Text
- View/download PDF
83. Dasatinib or Nilotinib Discontinuation in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients (pts) with Durably Undetectable BCR-ABL Transcripts: Interim Analysis of the STOP 2G-TKI Study with a Minimum Follow-up of 12 Months – on Behalf of the French CML Group Filmc
- Author
-
Rea, Delphine, primary, Nicolini, Franck E., additional, Tulliez, Michel, additional, Rousselot, Philippe, additional, Guilhot, Francois, additional, Gardembas, Martine, additional, Guerci, Agnès, additional, Coiteux, Valérie, additional, Legros, Laurence, additional, Guillerm, Gaelle, additional, Pignon, Jean Michel, additional, Giraudier, Stephane, additional, Etienne, Gabriel, additional, Villemagne, Bruno, additional, Escoffre, Martine, additional, Charbonnier, Aude, additional, and Mahon, Francois-Xavier, additional
- Published
- 2014
- Full Text
- View/download PDF
84. Autologous Stem Cell Transplantation (ASCT) for Patients Aged 60 Years or Older with Classical Hodgkin Lymphoma : A Retrospective Analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)
- Author
-
Stamatoullas, Aspasia, primary, Brice, Pauline, additional, Gueye, Mor Seny, additional, Chevallier, Patrice, additional, Bouabdallah, Reda, additional, Nguyenquoc, Stephanie, additional, Francois, Sylvie, additional, Turlure, Pascal, additional, Ceballos, Patrice, additional, Monjanel, Helene, additional, Bourhis, Jean-Henri, additional, Guillerm, Gaelle, additional, Mohty, Mohamad, additional, Biron, Pierre, additional, Cornillon, Jérôme, additional, Cordonnier, Catherine, additional, Bonmati, Caroline, additional, Tabrizi, Reza, additional, Huynh, Anne, additional, Bernard, Marc, additional, Caillot, Denis, additional, Peffault de Latour, Régis, additional, and Tilly, Hervé, additional
- Published
- 2014
- Full Text
- View/download PDF
85. Impact of CD3+ and CD34+ Doses in the Mobilized Peripheral Blood Stem Cell Grafts on the Outcome of Reduced-Intensity Conditioning Allogenic Transplantation from Matched Unrelated Donors for Acute Myeloid Leukemia – an Analysis from the Acute Leukemia Working Party of the EBMT
- Author
-
Czerw, Tomasz, primary, Labopin, Myriam, additional, Schmid, Christoph, additional, Cornelissen, Jan J., additional, Chevallier, Patrice, additional, Blaise, Didier, additional, Kuball, Jurgen H, additional, Milpied, Noel, additional, Cahn, Jean-Yves, additional, Lioure, Bruno, additional, Fegueux, Nathalie, additional, Clement, Laurence, additional, Sandstedt, Anna, additional, Maertens, Johan, additional, Guillerm, Gaelle, additional, Bordessoule, Dominique, additional, Mohty, Mohamad, additional, and Nagler, Arnon, additional
- Published
- 2014
- Full Text
- View/download PDF
86. Effect of Immune Modulation for Peripheral T-Cell Lymphoma in Response to Relapse after Allogeneic Hematopoietic Stem Cell Transplant: A Study of 63 Patients By the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC).
- Author
-
Mamez, Anne-Claire, primary, Levy, Vincent, additional, Chevallier, Patrice, additional, Blaise, Didier, additional, Vigouroux, Stephane, additional, Xhaard, Alienor, additional, Vincent, Laure, additional, Contentin, Nathalie, additional, Beguin, Yves, additional, Ifrah, Norbert, additional, Cahn, Jean-Yves, additional, Suarez, Felipe, additional, Yakoub-Agha, Ibrahim, additional, Turlure, Pascal, additional, Deconinck, Eric, additional, Lamy, Thierry, additional, Huynh, Anne, additional, Maury, Sébastien, additional, Fornecker, Luc Matthieu, additional, Bay, Jacques-Olivier, additional, Guillerm, Gaelle, additional, Maillard, Natacha, additional, Mohty, Mohamad, additional, and Nguyen, Stephanie, additional
- Published
- 2014
- Full Text
- View/download PDF
87. Comparable survival between HIV+ and HIV− non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation
- Author
-
Díez-Martín, José L., Balsalobre, Pascual, Re, Alessandro, Michieli, Mariagrazia, Ribera, José M., Canals, Carmen, Conde, Eulogio, Rosselet, Anne, Gabriel, Ian, Varela, Rosario, Allione, Bernardino, Cwynarski, Kate, Genet, Philippe, Espigado, Ildefonso, Biron, Pierre, Schmitz, Norbert, Hunter, Anne E., Ferrant, Augustin, Guillerm, Gaelle, Hentrich, Mark, Jurado, Manuel, Fernández, Pascual, Serrano, David, Rossi, Giuseppe, and Sureda, Anna
- Published
- 2009
- Full Text
- View/download PDF
88. Autologous stem-cell transplantation in patients with HIV-related lymphoma.
- Author
-
UCL - MED - Sciences médicales, Balsalobre, Pascual, Díez-Martín, José L, Re, Alessandro, Michieli, Mariagrazia, Ribera, José M, Canals, Carmen, Rosselet, Anne, Conde, Eulogio, Varela, Rosario, Cwynarski, Kate, Gabriel, Ian, Genet, Philippe, Guillerm, Gaelle, Allione, Bernardino, Ferrant, Augustin, Biron, Pierre, Espigado, Ildefonso, Serrano, David, Sureda, Anna, UCL - MED - Sciences médicales, Balsalobre, Pascual, Díez-Martín, José L, Re, Alessandro, Michieli, Mariagrazia, Ribera, José M, Canals, Carmen, Rosselet, Anne, Conde, Eulogio, Varela, Rosario, Cwynarski, Kate, Gabriel, Ian, Genet, Philippe, Guillerm, Gaelle, Allione, Bernardino, Ferrant, Augustin, Biron, Pierre, Espigado, Ildefonso, Serrano, David, and Sureda, Anna
- Abstract
PURPOSE: Peripheral-blood autologous stem-cell transplantation (ASCT) in patients with HIV-related lymphoma (HIV-Ly) has been reported as a safe and useful procedure. Herein we report the European Group for Blood and Marrow Transplantation experience on patients with HIV-Ly undergoing ASCT. PATIENTS AND METHODS: This was a retrospective, multicentric, registry-based analysis. RESULTS: Since 1999, 68 patients from 20 institutions (median age, 41 years; range, 29 to 62 years) were included, diagnosed with non-Hodgkin's lymphoma (NHL; n = 50) or Hodgkin's lymphoma (n = 18). At the time of ASCT, 16 patients were in first complete remission (CR1); 44 patients were in CR more than 1, partial remission, or chemotherapy-sensitive relapse (chemo-S); and eight patients had chemotherapy-resistant disease. The median number of CD34(+) cells infused was 4.5 x 10(6)/kg (range, 1.6 to 21.2 x 10(6)/kg). Median time to neutrophil and platelet engraftment were 11 days (range, 8 to 36 days) and 14 days (range, 6 to 455 days), respectively, with a cumulative incidence (CI) at 1 year of 95.6% and 87%, respectively. CI of nonrelapse mortality (NRM) was 7.5% at 12 months after ASCT, mainly because of bacterial infections. CI of relapse was 30.4% at 24 months, statistically related with not being in CR at ASCT (relative risk [RR] = 3.6), NHL histology other than diffuse large B-cell lymphoma (RR = 3.4), and use of more than two previous treatment lines (RR = 3). At a median follow-up of 32 months (range, 2 to 81 months), progression-free survival (PFS) was 56%. Patients not in CR or with refractory disease at ASCT had poorer PFS (RR = 2.4 and 4.8, respectively). CONCLUSION: Similarly to HIV-negative patients with lymphoma, ASCT is a useful treatment for patients with HIV-Ly and is associated with low NRM, mainly when performed in early stages and chemo-S disease.
- Published
- 2009
89. Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
- Author
-
UCL - MD/MINT - Département de médecine interne, Hulin, Cyrille, Facon, Thierry, Rodon, Philippe, Pegourie, Brigitte, Benboubker, Lotfi, Doyen, Chantal, Dib, Mamoun, Guillerm, Gaelle, Salles, Bruno, Eschard, Jean-Paul, Lenain, Pascal, Casassus, Philippe, Azais, Isabelle, Decaux, Olivier, Garderet, Laurent, Mathiot, Claire, Fontan, Jean, Lafon, Ingrid, Virion, Jean Marc, Moreau, Philippe, 49th Annual Meeting of the American-Society-of-Hematology, UCL - MD/MINT - Département de médecine interne, Hulin, Cyrille, Facon, Thierry, Rodon, Philippe, Pegourie, Brigitte, Benboubker, Lotfi, Doyen, Chantal, Dib, Mamoun, Guillerm, Gaelle, Salles, Bruno, Eschard, Jean-Paul, Lenain, Pascal, Casassus, Philippe, Azais, Isabelle, Decaux, Olivier, Garderet, Laurent, Mathiot, Claire, Fontan, Jean, Lafon, Ingrid, Virion, Jean Marc, Moreau, Philippe, and 49th Annual Meeting of the American-Society-of-Hematology
- Abstract
Purpose Until recently, melphalan and prednisone were the standards of care in elderly patients with multiple myeloma. The addition of thalidomide to this combination demonstrated a survival benefit for patients age 65 to 75 years. This randomized, placebo-controlled, phase III trial investigated the efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed myeloma. Patients and Methods Between April 2002 and December 2006, 232 previously untreated patients with myeloma, age 75 years or older, were enrolled and 229 were randomly assigned to treatment. All patients received melphalan (0.2 mg/kg/d) plus prednisone (2 mg/kg/d) for 12 courses (day 1 to 4) every 6 weeks. Patients were randomly assigned to receive 100 mg/d of oral thalidomide (n = 113) or placebo (n = 116), continuously for 72 weeks. The primary end point was overall survival. Results After a median follow-up of 47.5 months, overall survival was significantly longer in patients who received melphalan and prednisone plus thalidomide compared with those who received melphalan and prednisone plus placebo (median, 44.0 v 29.1 months; P = .028). Progression-free survival was significantly prolonged in the melphalan and prednisone plus thalidomide group (median, 24.1 v 18.5 months; P = .001). Two adverse events were significantly increased in the melphalan and prednisone plus thalidomide group: grade 2 to 4 peripheral neuropathy (20% v 5% in the melphalan and prednisone plus placebo group; P < .001) and grade 3 to 4 neutropenia (23% v 9%; P = .003). Conclusion This trial confirms the superiority of the combination melphalan and prednisone plus thalidomide over melphalan and prednisone alone for prolonging survival in very elderly patients with newly diagnosed myeloma. Toxicity was acceptable. J Clin Oncol 27: 3664-3670. (C) 2009 by American Society of Clinical Oncology
- Published
- 2009
90. Outcomes After Reduced-Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation (allo-SCT) In 163 Pediatric Patients (<18 years old): A Retrospective Study On Behalf Of The SFGM-TC
- Author
-
Strullu, Marion, primary, Labopin, Myriam, additional, De La Tour, Regis Peffaut, additional, Salmon, Alexandra, additional, Dalle, Jean-Hugues, additional, Fegueux, Nathalie, additional, Paillard, Catherine, additional, Michel, Gerard, additional, Rohrlich, Pierre, additional, Bertrand, Yves, additional, Jubert, Charlotte, additional, Beguin, Yves, additional, Cardine, Aude-Marie, additional, Guillerm, Gaelle, additional, Bourhis, Jean-Henri, additional, Lutz, Patrick, additional, Raus, Nicole, additional, Rialland, Fanny, additional, Mohty, Mohamad, additional, and Chevallier, Patrice, additional
- Published
- 2013
- Full Text
- View/download PDF
91. Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery
- Author
-
Ianotto, Jean-Christophe, primary, Ngo Sack, Françoise, additional, Couturier, Marie-Anne, additional, Tempescul, Adrian, additional, Mugnier, Nathalie, additional, Delepine, Pascal, additional, Guillerm, Gaelle, additional, and Berthou, Christian, additional
- Published
- 2013
- Full Text
- View/download PDF
92. Impact of Azacitidine Before Allogeneic Stem-Cell Transplantation for Myelodysplastic Syndromes: A Study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies
- Author
-
Damaj, Gandhi, primary, Duhamel, Alain, additional, Robin, Marie, additional, Beguin, Yves, additional, Michallet, Mauricette, additional, Mohty, Mohamad, additional, Vigouroux, Stephane, additional, Bories, Pierre, additional, Garnier, Alice, additional, El Cheikh, Jean, additional, Bulabois, Claude-Eric, additional, Huynh, Anne, additional, Bay, Jacques-Olivier, additional, Legrand, Faeyzeh, additional, Deconinck, Eric, additional, Fegueux, Nathalie, additional, Clement, Laurence, additional, Dauriac, Charles, additional, Maillard, Natacha, additional, Cornillon, Jérôme, additional, Ades, Lionel, additional, Guillerm, Gaelle, additional, Schmidt-Tanguy, Aline, additional, Marjanovic, Zora, additional, Park, Sophie, additional, Rubio, Marie-Thérèse, additional, Marolleau, Jean-Pierre, additional, Garnier, Federico, additional, Fenaux, ierre, additional, and Yakoub-Agha, Ibrahim, additional
- Published
- 2012
- Full Text
- View/download PDF
93. Discontinuation of Second Generation (2G) Tyrosine Kinase Inhibitors (TKI) in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients with Stable Undetectable BCR-ABL Transcripts
- Author
-
Rea, Delphine, primary, Rousselot, Philippe, additional, Guilhot, François, additional, Tulliez, Michel, additional, Nicolini, Franck E., additional, Guerci-Bresler, Agnès, additional, Legros, Laurence, additional, Gardembas, Martine, additional, Giraudier, Stephane, additional, Guillerm, Gaelle, additional, and Mahon, Francois-Xavier, additional
- Published
- 2012
- Full Text
- View/download PDF
94. Treatment of Relapse After Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndrome: A Large-Scale Study On Behalf of the Société Française De Greffe De Moelle Et De Thérapie Cellulaire (SFGM-TC)
- Author
-
Guièze, Romain, primary, Damaj, Gandhi, additional, Robin, Marie, additional, Mohty, Mohamad, additional, Michallet, Mauricette, additional, Tabrizi, Reza, additional, Beguin, Yves, additional, Blaise, Didier, additional, Bulabois, Claude-Eric, additional, Legrand, Faezeh, additional, Huynh, Anne, additional, Cornillon, Jérôme, additional, Contentin, Nathalie, additional, Suarez, Felipe, additional, Lioure, Bruno, additional, Maillard, Natacha, additional, Clement, Laurence, additional, Guillerm, Gaelle, additional, Rubio, Marie T, additional, Garnier, Federico, additional, and Yakoub-Agha, Ibrahim, additional
- Published
- 2012
- Full Text
- View/download PDF
95. Allogeneic Hematopoietic Stem Cell Transplantation for T-Prolymphocytic leukemia: A Retrospective Analysis From the Societe française De Greffe De Moelle Et De Therapie Cellulaire
- Author
-
Guillaume, Thierry, primary, Beguin, Yves, additional, Leblond, Véronique, additional, Blaise, Didier, additional, Milpied, Noel, additional, Deconinck, Eric, additional, Cordonnier, Catherine, additional, Cornillon, Jerome, additional, Contentin, Nathalie, additional, Guillerm, Gaelle, additional, Fegueux, Nathalie, additional, Turlure, Pascal, additional, Salmon, Alexandra, additional, de Revel, Thierry, additional, and Mohty, Mohamad, additional
- Published
- 2012
- Full Text
- View/download PDF
96. Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation
- Author
-
Dagorne, Anaig, primary, Douet-Guilbert, Nathalie, additional, Quintin-Roue, Isabelle, additional, Guillerm, Gaelle, additional, Couturier, Marie-Anne, additional, Berthou, Christian, additional, and Ianotto, Jean-Christophe, additional
- Published
- 2012
- Full Text
- View/download PDF
97. Favorable Impact of Post-ASCT Consolidative Immunotherapy with RITUXIMAB, rINF-a2b and rIL2 on Overall Survival and Progression-Free Survival in Advanced Stage or Relapsed/Refractory Follicular Lymphoma: Results of a Phase II Study
- Author
-
Eveillard, Jean-Richard, primary, Ianotto, Jean-Christophe, additional, Tempescul, Adrian, additional, Guillerm, Gaelle, additional, Dalbiès, Florence, additional, Saad, Hussam, additional, Calloc'h, Ronan LE, additional, Dagorn, Anaïg, additional, Sack, Françoise N'go, additional, and Berthou, Christian, additional
- Published
- 2011
- Full Text
- View/download PDF
98. Impact of Antithymocyte Globulin-Containing Conditioning Regimens on Patients Undergoing Allogeneic Stem Cell Transplantation for Progressive Myelodysplastic Syndrome: A Report From the SFGM-TC Group
- Author
-
Yakoub-Agha, Ibrahim, primary, Damaj, Gandhi, additional, Robin, Marie, additional, Vigouroux, Stephane, additional, Garnier, Alice, additional, Michallet, Mauricette, additional, El-Cheikh, Jean, additional, Lioure, Bruno, additional, Simon, Audrey, additional, Bay, Jacques-Olivier, additional, Bordigoni, Pierre, additional, Contentin, Nathalie, additional, Maillard, Natacha, additional, Deconinck, Eric, additional, Lapusan, Simona, additional, Guillerm, Gaelle, additional, Legrand, Faezeh, additional, Marry, Evelyne, additional, Mohty, Mohamad, additional, and Duhamel, Alain, additional
- Published
- 2011
- Full Text
- View/download PDF
99. Clofarabine Containing Conditioning Regimen for Allo-SCT in AML/ALL Patients: A Survey From the Acute Leukemia Working Party of EBMT
- Author
-
Chevallier, Patrice, primary, Labopin, Myriam, additional, Buchholz, Stefanie, additional, Ganser, Arnold, additional, Ciceri, Fabio, additional, Lioure, Bruno, additional, Faul, Christoph, additional, Guillerm, Gaelle, additional, Finke, Juergen, additional, Huynh, Anne, additional, Schubert, Joerg, additional, Kolb, Hans Jochem, additional, Polge, Emmanuelle, additional, Nagler, Arnon, additional, and Mohty, Mohamad, additional
- Published
- 2011
- Full Text
- View/download PDF
100. Pancytopaenia secondary to bone marrow dissemination of Merkel cell carcinoma in a patient with Waldenström macroglobulinaemia
- Author
-
LE GALL-IANOTTO, Christelle, additional, COQUART, Nolwenn, additional, IANOTTO, Jean-Christophe, additional, GUILLERM, Gaelle, additional, GRALL, Camille, additional, QUINTIN-ROUE, Isabelle, additional, MARION, Veronique, additional, GRECO, Matthieu, additional, BERTHOU, Christian, additional, and MISERY, Laurent, additional
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.